Tabelecleucel

Phase 3Cell therapy

AAtara Biotherapeutics

Tabelecleucel is one of 2 biologic programs targeting Lymphoproliferative Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoproliferative DiseaseRecruiting

Epstein-Barr Virus (EBV)-Associated DiseasesActive, not recruiting

Lymphoproliferative DiseasePhase 3

Recruiting

Epstein-Barr Virus (EBV)-Associated DiseasesPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Lymphoproliferative Disease

#DrugCompanyPhaseTrials

Tabelecleucel

AAtara Biotherapeutics

Phase 3

1 2

EBV MRNA Vaccine

WWest China Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Epstein-Barr Virus (EBV)-Associated Diseases

NCT04554914

Q3 2030

Phase 3Recruiting

Lymphoproliferative Disease

NCT03394365

Clinical

Trials by Indication[1]

Epstein Barr Virus1 trial

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

No longer available·AAtara Biotherapeutics··NCT02822495

Nasopharyngeal Carcinoma1 trial

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Terminated·AAtara Biotherapeutics·Phase 1/2·NCT03769467·12 enrolled

Lymphoproliferative Disease1 trial

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Recruiting·PPierre Fabre Medicament·Phase 3·NCT03394365·115 enrolled

Epstein-Barr Virus (EBV)-Associated Diseases1 trial

An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)

Active, not recruiting·PPierre Fabre Medicament·Phase 2·NCT04554914·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tabelecleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tabelecleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tabelecleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atara Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: AAtara Biotherapeutics

Tabelecleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2030

Trials by Indication[1]

Epstein Barr Virus1 trial

Nasopharyngeal Carcinoma1 trial

Lymphoproliferative Disease1 trial

Epstein-Barr Virus (EBV)-Associated Diseases1 trial

References

Drug Info

Quick Facts

Related News